Nyrada (ASX:NYR), a clinical-stage biotechnology company developing TRPC ion channel inhibitors, has received approval from the Human Research Ethics Committee to commence its Phase 2a clinical trial of Xolatryp for treating myocardial ischemia reperfusion injury in heart attack patients.
The multicentre, randomised, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of Xolatryp in approximately 200 patients undergoing primary percutaneous coronary intervention or angioplasty with stenting.
While safety remains the trial's primary endpoint, secondary measures will include cardiac function, extent of cardiac injury, biomarker analysis, and incidence of arrhythmias.
Patient recruitment and dosing are expected to begin in March, with up to ten Australian hospitals participating initially.